SCN2A Polymorphisms Are Associated With Response to Valproic Acid in Paediatric Population(Pakistan)

Plain-language summary

This study examined how polymorphisms in the SCN2A gene relate to response to Valproic Acid in children with epilepsy. Pakistani children aged 1-12 who had experienced at least two seizures and were newly started on Valproic Acid were included. It was a non-phase study that has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

Riphah International University

Intervention

Valproic Acid

Start date

12/1/2023

Estimated completion

8/31/2024

Countries

Pakistan

Related genes

Locations

• Islamabad, Pakistan

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Epileptic Pakistani individuals of age between 1 to 12 years of either sex
* Each patient had experienced two or more clinically confirmed, spontaneous epileptic seizures in the past.
* Newly diagnosed patients started VPA 20 mg/kg (drug of the same brand was used for every patient throughout the study).

Exclusion Criteria:

* Patients taking any other anti-epileptic drug.
* Patients taking medications that interact with VPA.
* Patients with moderate or severe systemic diseases